MX2024010008A - Formas polimorficas y metodos de produccion de formas polimorficas de un compuesto. - Google Patents
Formas polimorficas y metodos de produccion de formas polimorficas de un compuesto.Info
- Publication number
- MX2024010008A MX2024010008A MX2024010008A MX2024010008A MX2024010008A MX 2024010008 A MX2024010008 A MX 2024010008A MX 2024010008 A MX2024010008 A MX 2024010008A MX 2024010008 A MX2024010008 A MX 2024010008A MX 2024010008 A MX2024010008 A MX 2024010008A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorphic forms
- compound
- methods
- producing
- forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 102000004217 thyroid hormone receptors Human genes 0.000 abstract 1
- 108090000721 thyroid hormone receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311869P | 2022-02-18 | 2022-02-18 | |
| PCT/US2023/012898 WO2023158607A1 (en) | 2022-02-18 | 2023-02-13 | Polymorphic forms and methods of producing polymorphic forms of a compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010008A true MX2024010008A (es) | 2024-08-22 |
Family
ID=87578977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010008A MX2024010008A (es) | 2022-02-18 | 2023-02-13 | Formas polimorficas y metodos de produccion de formas polimorficas de un compuesto. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250034183A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4479409A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025508746A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240152889A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119053613A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023221889A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3252569A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024010008A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023158607A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| AU2006249347A1 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP4775207A2 (en) * | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
-
2023
- 2023-02-13 CA CA3252569A patent/CA3252569A1/en active Pending
- 2023-02-13 KR KR1020247031018A patent/KR20240152889A/ko active Pending
- 2023-02-13 MX MX2024010008A patent/MX2024010008A/es unknown
- 2023-02-13 WO PCT/US2023/012898 patent/WO2023158607A1/en not_active Ceased
- 2023-02-13 AU AU2023221889A patent/AU2023221889A1/en active Pending
- 2023-02-13 CN CN202380034735.3A patent/CN119053613A/zh active Pending
- 2023-02-13 EP EP23756786.2A patent/EP4479409A4/en active Pending
- 2023-02-13 JP JP2024548633A patent/JP2025508746A/ja active Pending
- 2023-02-13 US US18/836,713 patent/US20250034183A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025508746A (ja) | 2025-04-10 |
| KR20240152889A (ko) | 2024-10-22 |
| CN119053613A (zh) | 2024-11-29 |
| CA3252569A1 (en) | 2023-08-24 |
| US20250034183A1 (en) | 2025-01-30 |
| WO2023158607A1 (en) | 2023-08-24 |
| EP4479409A4 (en) | 2025-10-22 |
| AU2023221889A1 (en) | 2024-08-15 |
| EP4479409A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202305593B (en) | Crystalline form iii of melanocortin receptor agonist compound and method for preparing same | |
| ZA202305594B (en) | Crystalline form i of melanocortin receptor agonist compound, and method for preparing same | |
| JOP20230084A1 (ar) | الشكل البلوري iv لمركب ناهض مستقبلات الميلانوكورتين وطريقة تحضيره | |
| MX2022015165A (es) | Formas y composiciones de un agonista beta adrenégico. | |
| PE20050761A1 (es) | Polimorfo cristalino de una sal de bisulfato como antagonista del receptor de trombina | |
| ZA201805185B (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| CO2023006517A2 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma | |
| UA83720C2 (ru) | Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
| ZA202305591B (en) | Amorphous melanocortin-4 receptor agonist | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025011564A (es) | Formas cristalinas de un compuesto para la degradacion dirigida del receptor de androgenos | |
| MX2024007457A (es) | Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas. | |
| WO2020016302A8 (en) | A xinafoate salt of a jak inhibiting compound | |
| MX2023013044A (es) | Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma. | |
| MX2025009371A (es) | Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello | |
| MX2025011614A (es) | Forma cristalina de un antagonista de ep4 | |
| MX2025011536A (es) | Forma polimorfica del clorhidrato de pitolisant | |
| MX2024013889A (es) | Derivado de anillo de benceno sustituido con imidazopiridazina, método de preparación, composición farmacéutica y uso | |
| MX2023010606A (es) | Formas de sales y sólidas de un inhibidor de cinasas. | |
| MX2025000464A (es) | Forma cristalina de un esteroide neuroactivo | |
| MX2025000159A (es) | Formas cristalinas de un esteroide neuroactivo | |
| MX2023002068A (es) | Nuevos compuestos que tienen actividad inhibidora sobre el receptor de prostaglandina e2 y usos de los mismos. | |
| WO2023278403A3 (en) | Crystalline hydrochloride salts of substituted tryptamines | |
| MX2022001619A (es) | Un metodo para preparar ivosidenib y un intermediario del mismo. | |
| MX2025013728A (es) | Antagonista del receptor acoplado a la proteina g |